Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs By: TalkMarkets February 06, 2015 at 04:15 AM EST The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014. Read More >> Related Stocks: Alexion Pharmaceuticals Amgen Biogen Idec Gilead Sciences Nasdaq Biotechnology Ishares ETF